Gln(27)-> Glu beta(2)-Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol

Troncoso R.; Moraga, F; Chiong M.; Roldan, J; Bravo, R.; Valenzuela R.; Diaz-Araya, G; del Campo, A; Sanhueza C.; Rodríguez A.; Vukasovic, JL; Mellado R.; Greig D.; Castro, PF; Lavandero S.

Abstract

We investigated the clinical response of chronic heart failure patients with β2-adrenergic receptor Gln27→Glu polymorphism treated for 6 months with carvedilol, a α/β-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27→Gluβ2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu 27β2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln27β2- adrenergic receptor variant. © 2009 Nordic Pharmacological Society.

Más información

Título según WOS: Gln(27)-> Glu beta(2)-Adrenergic Receptor Polymorphism in Heart Failure Patients: Differential Clinical and Oxidative Response to Carvedilol
Título según SCOPUS: Gln27?Glu?2-adrenergic receptor polymorphism in heart failure patients: Differential clinical and oxidative response to carvedilol
Título de la Revista: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Volumen: 104
Asunto: 5
Editorial: Wiley
Fecha de publicación: 2009-01-01
Página de inicio: 374
Página final: 378
Idioma: English
DOI/URL:

10.1111/j.1742-7843.2008.00370.x

Identificador: 10.1111/j.1742-7843.2008.00370.x
Notas: ISI, SCOPUS